Kiora Pharmaceuticals, Inc. – NASDAQ:KPRX
Kiora Pharmaceuticals stock price today
Kiora Pharmaceuticals stock price monthly change
Kiora Pharmaceuticals stock price quarterly change
Kiora Pharmaceuticals stock price yearly change
Kiora Pharmaceuticals key metrics
Market Cap | 9.60M |
Enterprise value | N/A |
P/E | -0.2 |
EV/Sales | N/A |
EV/EBITDA | 0.16 |
Price/Sales | N/A |
Price/Book | 0.23 |
PEG ratio | N/A |
EPS | -1.37 |
Revenue | N/A |
EBITDA | 9.84M |
Income | 2.80M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeKiora Pharmaceuticals stock price history
Kiora Pharmaceuticals stock forecast
Kiora Pharmaceuticals financial statements
| Jun 2023 | 0 | -2.61M | |
|---|---|---|---|
| Sep 2023 | 0 | -5.76M | |
| Dec 2023 | 283.87K | -2.26M | -799.17% |
| Mar 2024 | 16M | 13.45M | 84.08% |
| Dec 2023 | 283.87K | -2.26M | -799.17% |
|---|---|---|---|
| Mar 2024 | 16M | 13.45M | 84.08% |
| Oct 2025 | 5.67M | -23.64M | -416.54% |
| Dec 2025 | 4.77M | -23.64M | -495.07% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 19884943 | 6.24M | 31.39% |
|---|---|---|---|
| Sep 2023 | 15896443 | 7.79M | 49.02% |
| Dec 2023 | 13711870 | 7.60M | 55.44% |
| Mar 2024 | 42440007 | 7.53M | 17.76% |
| Jun 2023 | -1.38M | 0 | 5.93M |
|---|---|---|---|
| Sep 2023 | -2.52M | 0 | 0 |
| Dec 2023 | -2.58M | -236 | -486.42K |
| Mar 2024 | 13.62M | 0 | 15.24M |
Kiora Pharmaceuticals alternative data
| Aug 2023 | 12 |
|---|---|
| Sep 2023 | 12 |
| Oct 2023 | 12 |
| Nov 2023 | 12 |
| Dec 2023 | 12 |
| Jan 2024 | 12 |
| Feb 2024 | 12 |
| Mar 2024 | 12 |
| Apr 2024 | 12 |
| May 2024 | 12 |
| Jun 2024 | 12 |
| Jul 2024 | 12 |
Kiora Pharmaceuticals other data
| Period | Buy | Sel |
|---|---|---|
| Jun 2024 | 8260 | 0 |
| Insider | Compensation |
|---|---|
| Mr. Stephen From (1963) Executive Chairman | $560,000 |
| Ms. Sarah Romano (1980) Chief Financial Officer | $324,360 |
-
What's the price of Kiora Pharmaceuticals stock today?
One share of Kiora Pharmaceuticals stock can currently be purchased for approximately $2.65.
-
When is Kiora Pharmaceuticals's next earnings date?
Unfortunately, Kiora Pharmaceuticals's (KPRX) next earnings date is currently unknown.
-
Does Kiora Pharmaceuticals pay dividends?
No, Kiora Pharmaceuticals does not pay dividends.
-
How much money does Kiora Pharmaceuticals make?
Kiora Pharmaceuticals has a market capitalization of 9.60M.
-
What is Kiora Pharmaceuticals's stock symbol?
Kiora Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "KPRX".
-
What is Kiora Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Kiora Pharmaceuticals?
Shares of Kiora Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Kiora Pharmaceuticals's key executives?
Kiora Pharmaceuticals's management team includes the following people:
- Mr. Stephen From Executive Chairman(age: 62, pay: $560,000)
- Ms. Sarah Romano Chief Financial Officer(age: 45, pay: $324,360)
-
How many employees does Kiora Pharmaceuticals have?
As Jul 2024, Kiora Pharmaceuticals employs 12 workers.
-
When Kiora Pharmaceuticals went public?
Kiora Pharmaceuticals, Inc. is publicly traded company for more then 10 years since IPO on 13 Feb 2015.
-
What is Kiora Pharmaceuticals's official website?
The official website for Kiora Pharmaceuticals is kiorapharma.com.
-
Where are Kiora Pharmaceuticals's headquarters?
Kiora Pharmaceuticals is headquartered at 1371 East 2100 South, Salt Lake City, UT.
-
How can i contact Kiora Pharmaceuticals?
Kiora Pharmaceuticals's mailing address is 1371 East 2100 South, Salt Lake City, UT and company can be reached via phone at +7 817888869.
Kiora Pharmaceuticals company profile:
Kiora Pharmaceuticals, Inc.
kiorapharma.comNASDAQ
12
Biotechnology
Healthcare
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, as well as for treating non-infectious posterior uveitis; and KIO-201, an eye drop, which is in Phase 3 clinical trial for treating patients undergoing PRK surgery for corneal wound repair after refractive surgery. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.
Salt Lake City, UT 84105
CIK: 0001372514
ISIN: US49721T3095
CUSIP: 49721T101
